Trial Profile
Study for the add-on effect of vitamin K to Sorafenib treatment for hepatocellular carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Jun 2017
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Vitamin K (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 22 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2017 Primary endpoint (Overall survival) has not been met as per the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology